FDA recall record

Teva Pharmaceuticals USA Lidocaine 2.5% and Prilocaine 2.5% Cream, USP recall — FDA D-0794-2022

cGMP Deviations

Class IIclassification
D-0794-2022official record ID
May 4, 2022report date

Recall record at a glance

Official recordD-0794-2022
CategoryDrug Recalls
ClassificationClass II
FDA record statusTerminated
Recalling firmTeva Pharmaceuticals USA Inc.
Report dateMay 4, 2022
Recall initiation dateApr 15, 2022
Quantity353964 units
LocationParsippany, NJ, United States

Official product description

Lidocaine 2.5% and Prilocaine 2.5% Cream, USP, packaged in a) 5 g tubes (NDC 0591-2070-72), b) 30 g tubes (NDC 0591-2070-30), Rx Only, Manufactured by: Teligent Pharma, Inc., Buena, NJ 08310, USA, Distributed by: Actavis Pharma, Inc., Parsippany, NJ 07054, USA

Why the product was recalled

cGMP Deviations

Distribution information

Nationwide within the United States

How to read the classification

FDA Class II indicates a situation in which use of or exposure to the product may cause temporary or medically reversible adverse health consequences, or where the probability of serious consequences is remote. The classification shown here comes from the FDA record.

Additional record details

Recall type: Voluntary: Firm initiated. Initial notification: not stated.

What to do next

If you believe you have the recalled product, use the recall number and firm information above to confirm the official notice and follow the instructions issued by the FDA, recalling firm, retailer or product manufacturer. For drugs and medical devices, decisions about treatment or medical care should be discussed with a qualified health professional.

About this record

Recall Lookup USA preserves the most complete source information successfully retrieved. We do not create missing facts or infer affected lots or VINs. The official record may still change, so use the identifier above when verifying current instructions.

FDA source limitation: openFDA enforcement reports are a reference dataset, not a live public-alert or recall-lifecycle service. FDA notes that enforcement-report status may not be updated after classification. Confirm current actions with the FDA, recalling firm or appropriate healthcare professional when relevant.

Related recall records

Other records from the same recalling company are shown first when available.

DrugApr 29, 2026

Claravis recall — FDA D-0521-2026

Failed Impurities/Degradation Specifications: Out of specification for specific impurity Tretinoin

Class IIFDA: OngoingTeva Pharmaceuticals USA, Inc